Balloon-Occluded Transcatheter Arterial Chemoembolization (b-TACE) for Hepatocellular Carcinoma Performed with Polyethylene-Glycol Epirubicin-Loaded Drug-Eluting Embolics: Safety and Preliminary Results

• DOI: 10.1007/s00270-019-02192-y
• Publication Date: 2019-03-06T20:27:47Z
• Authors: Pierleone Lucatelli; Luca Ginnani Corr...; Gianluca De Rubeis; Bianca Rocco; Fabrizio Basilico; Alessandro Cannavale; Pier Giorgio Nardis; Mario Corona; Luca Saba; Carlo Catalano; Mario Bezzi
• Keywords: Transcatheter arterial chemoembolization

To report technical success, safety profile and oncological results of balloon-occluded transcatheter arterial chemoembolization using a balloon micro-catheter epirubicin-loaded polyethylene-glycol (PEG) microsphere (100 ± 25 µm 200 50 µm) in patients with hepatocellular carcinoma (HCC). This is single-centre, single-arm, retrospective study 6-month follow-up. Twenty-two (Child–Pugh A 68% [15/22], B 32% [7/22]; age 67.05 14 years) 29 HCC were treated 24 procedures. Technical success defined: ability to place the within required vascular segment, stump pressure drops assessment deposition. Laboratory pre/post-procedural complications analysed, respectively, according Common Terminology Criteria for Adverse Events (CTCAEv5) CIRSE system. Postembolization syndrome (PES) was defined as fever and/or nausea pain onset. Oncological evaluated m-RECIST criteria CT/MRI imaging at 1 3–6 months. In partial responder patients, tumour volume compared. Pre-planned feeder reached all cases. Pressure drop average 51.1 21.6 mmHg. Exclusive target embolization achieved 14/24 procedures (58.3%). test modifications grade 1. 4/24 adverse events occurred (17%): pseudo-aneurysm (grade 3), liver abscess 2) 2 asymptomatic segmentary biliary tree dilatations 2). PES 8/24 (33%). The complete response months 44.8% (13/29) 52.9% (9/17), respectively. 55% (16/29) 4/17 (23.5%), Among percentage reduction 64.9 27.3%. Epirubicin-loaded PEG b-TACE technically feasible, safe effective procedure treatment.